APA
Click to copy
Calais, J., Fendler, W., Eiber, M., Gartmann, J., Chu, F., Nickols, N., … Herrmann, K. (2017). Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. Journal of Nuclear Medicine.
Chicago/Turabian
Click to copy
Calais, J., W. Fendler, M. Eiber, J. Gartmann, F. Chu, N. Nickols, R. Reiter, et al. “Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.” Journal of Nuclear Medicine (2017).
MLA
Click to copy
Calais, J., et al. “Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.” Journal of Nuclear Medicine, 2017.
BibTeX Click to copy
@article{j2017a,
title = {Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence},
year = {2017},
journal = {Journal of Nuclear Medicine},
author = {Calais, J. and Fendler, W. and Eiber, M. and Gartmann, J. and Chu, F. and Nickols, N. and Reiter, R. and Rettig, M. and Marks, L. and Ahlering, T. and Huynh, L. and Slavik, R. and Gupta, Pawan K and Quon, A. and Allen-Auerbach, M. and Czernin, J. and Herrmann, K.}
}
In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05–202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3–6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.